Systemic progesterone therapy - Oral, vaginal, injections and even transdermal?

Maturitas

Volumn 79, Issue 3, 2014, Pages 248-255

  Ruan, Xiangyan ^a   Mueck, Alfred O ^a,b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Oral; Parenteral; Progesterone therapy; Transdermal; Vaginal

Indexed keywords

ESTROGEN; HYDROXYPROGESTERONE CAPROATE; PROGESTERONE; GESTAGEN;

CREAM; DRUG BLOOD LEVEL; ENDOMETRIAL PROTECTION; ENDOMETRIUM; ESTROGEN THERAPY; GEL; HUMAN; LUTEAL PHASE; MEDICAL HISTORY; MENOPAUSAL SYNDROME; META ANALYSIS (TOPIC); POSTMENOPAUSE; PREGNANCY; PREMATURE LABOR; PREMATURITY; PRIMARY PREVENTION; PROGESTERONE BLOOD LEVEL; PROPHYLAXIS; PROTECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SKIN PROTECTION; SYSTEMATIC REVIEW (TOPIC); SYSTEMIC THERAPY; TREATMENT INDICATION; UNITED STATES; FEMALE; INJECTION; INTRADERMAL DRUG ADMINISTRATION; INTRAVAGINAL DRUG ADMINISTRATION; NEWBORN; ORAL DRUG ADMINISTRATION; PREMATURE BIRTH;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, INTRAVAGINAL; ADMINISTRATION, ORAL; FEMALE; HUMANS; INFANT, NEWBORN; INJECTIONS; PREGNANCY; PREMATURE BIRTH; PROGESTERONE; PROGESTINS;

EID: 84908500593     PISSN: 03785122     EISSN: 18734111     Source Type: Journal    
DOI: 10.1016/j.maturitas.2014.07.009     Document Type: Review

References (88)

1. C.L. Williams, and G.M. Stancel Estrogens and progestins L.S. Goodman, A. Gilman, The pharmacological basis of therapeutics 9th ed. 1996 Pergamon Press Elmsford, Oxford 1411 1440
2. N. Chabbert Buffet, C. Djakoure, S.C. Maitre, and P. Bouchard Regulation of the human menstrual cycle Front Neuroendocrinol. 19 1998 151 186
3. J.D. Graham, and C.L. Clarke Physiological action of progesterone in target tissues Endocr Rev 18 1997 502 519
4. J.T. Bradbury, and W.E. Brown Secretory and decidual changes induced in the endometrium of oophorectomized women by administration of estrogen and progesterone J Clin Endocrinol Metab 11 1951 267 276
5. J.R.G. Challis, S.G. Matthews, W. Gibb, and S.J. Lye Endocrine and paracrine regulation of birth at term and preterm Endocr Rev 21 2000 514 550
6. S.K. Dey, H. Lim, and S.K. Das Molecular cues to implantation Endocr Rev 25 2004 341 373
7. K.M. Scarpin, J.D. Graham, P.A. Mote, and C.L. Clarke Progesterone action in human tissues: regulation by progesterone receptor (PR) isoform expression, nuclear positioning and coregulator expression Nucl Recept Signal 7 2009 e009
8. P. Kastner, A. Krust, and B. Turcotte Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B EMBO J 9 1990 1603 1614
9. J.D. Graham, A.R. Hanson, A.J. Croft, A.H. Fox, and C.L. Clarke Nuclear matrix binding is critical for progesterone receptor movement into nuclear foci FASEB J 23 2009 546 556
10. R.L. Arnett-Mansfield, A. DeFazio, P.A. Mote, and C.L. Clarke Subnuclear distribution of progesterone receptors A and B in normal and malignant endometrium J Clin Endocrinol Metab 89 2004 1429 1442
11. R.L. Arnett-Mansfield, J.D. Graham, and A.R. Hanson Focal subnuclear distribution of progesterone receptor is ligand dependent and associated with transcriptional activity Mol Endocrinol 21 2007 14 29
12. D.S. Loose, and G.M. Stancel Estrogens and progestins L.L. Brunton, Godman & Gilman's the pharmacological basis of therapeutics 11th ed. 2006 McGras-Hill New York, NY 1541 1571
13. R. Morville, F. Dray, J. Reynier, and J. Barrat Biodisponibilité de la progestérone naturelle administrée par voie orale. Mesure des concentrations du stéroïde dans le plasma, l'endomêtre et le tissu mammaire J Gynecol Obstet Biol Reprod 11 1982 355 363
14. Utrogest Fachinformation der Dr. Kade Besins Pharma GmbH. Stand. August 2011.
15. Writing Group for the PEPI trial Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The postmenopausal estrogen/progestin interventions (PEPI) trial JAMA 275 1996 370 375
16. C. Pélissier, M. Maroni, and H. Yaneva Chlormadinone acetate versus micronized progesterone in the sequential combined hormone replacement therapy of the menopause Maturitas 40 2001 85 94
17. T. Van Gorp, and P. Neven Endometrial safety of hormone replacement therapy: review of literature Maturitas 42 2004 93 104
18. R.J. Santen, D.C. Allred, and S.P. Ardoin Endocrine Society. Postmenopausal hormone therapy: an Endocrine Society scientific statement J Clin Endocrinol Metab 95 7 Suppl. 1 2010 s1 s66
19. J.E. Manson The kronos early estrogen prevention study by Charlotte Barker Womens Health (Lond Engl) 9 2013 9 11
20. N. Santoro The menopausal transition Am J Med 118 Suppl 12B 2005 8 13
21. D.S. Saarikoski, M. Yliskoski, and I. Penttila Sequential use of norethisterone and natural progesterone in pre-menopausal bleeding disorders Maturitas 12 1990 89 97
22. M.M. Shangold, M.J. Zinaman, and T.P. Tomai Factors associated with withdrawal bleeding after administration of oral micronized progesterone in women with secondary amenorrhea Fertil Steril 56 1991 1040 1047
23. P. Devroey, G. Palermo, and C. Bourgain Progesterone administration in patients with absent ovaries Int J Fertil 34 1989 188 193
24. R.A. Miles, R.J. Paulson, and R.A. Lobo Pharmacokinetics and endometrial tissue levels of progesterone after administration by intramuscular and vaginal routes: a comparative study Fertil Steril 63 1994 485 490
25. E. Cicinelli, D. De Ziegler, and C. Bulletti Direct transport of progesterone from vagina to uterus Obstet Gynecol 95 2000 403 406
26. M. van der Linden, K. Buckingham, and C. Farquhar Luteal phase support for assisted reproduction cycles Cochrane Database Syst Rev 10 2011 CD009154
27. A.M. Propst, J.A. Hill, and E.S. Ginsburg A randomized study comparing Crinone 8% and intramuscular progesterone supplementation in in vitro fertilization - embryo transfer cycles Fertil Steril 79 2001 1144 1149
28. R.F. Casper Luteal phase support for frozen embryo transfer cycles: intramuscular or vaginal progesterone Fertil Steril 101 2014 627 628
29. M. Sator, M. Radicioni, and B. Cometti Pharmacokinetics and safety profile of a novel progesterone aqueous formulation administered by the s.c. route Gynecol Endocrinol 29 2013 205 208
30. G. Lockwood, G. Griesinger, and B. Cometti Onbehalf of 13 European Centers Subcutaneous progesterone versus vaginal progesterone gel for luteal phase support in in vitro fertilization: a noninferiority randomized controlled study Fertil Steril 101 2014 112 119
31. P. Devroey, J. Smitz, C. Bourgain, and A. Van Steirteghem Only micronized progesterone is needed to substitute the luteal phase in stimulated cycles Contracept Fertil Sex 20 1992 7 8
32. J.I. Smitz, P. Devroey, and B. Faguer A prospective randomized comparison on intramuscular or intravaginal natural progesterone as a luteal phase and early pregnancy supplement Hum Reprod 7 1992 168 175
33. G. Griesinger, and K. Diedrich Die vaginale Anwendung von natürlichem Progesteron als Lutealphasenunterstützung nach IVF und Embryotransfer Geburts Frauenheilk 66 2006 655 664
34. E. Vaisbuch, D. de Ziegler, and M. Leong Luteal-phase support in assisted reproduction treatment: real-life practices reported worldwide by an updated website-based survey Reprod Biomed Online 28 2014 330 335
35. M.F. Greene Progesterone and preterm delivery - Deja vu all over again N Engl J Med 348 2003 2453 2455
36. P.J. Meis, M. Klebanoff, and E. Thom National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate N Engl J Med 348 2003 2379 2385
37. E.R. Norwitz, and A.B. Caughey Progesterone supplementation and the prevention of preterm birth Rev Obstet Gynecol 4 2011 60 72
38. E.B. Fonseca, E. Celik, and M. Parra for the Fetal Medicine Foundation Second Trimester Screening Group: progesterone and the risk of preterm birth among women with a short cervix N Engl J Med 357 2007 462 469
39. S.S. Hassan, R. Romero, and D. Vidyadhari Pregnant trial. Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double-blind, plazebo-controlled trial Ultrasound Obstet Gynecol 38 2011 18 31
40. R. Romero, K. Nicolaides, and A. Conde-Agudelo Vaginal progesterone in women with an asymptomatic sonographic short cervix in the midtrimester decreases preterm delivery and neonatal morbidity: a systematic review and metaanalysis of individual patient data Am J Obstet Gynecol 206 124 2012 e1 e19
41. Society for Maternal-Fetal Medicine Publications Committee, with assistance of Vincenzo Berghella Progesterone and preterm birth prevention: translating clinical trials data into clinical practice Am J Obstet Gynecol 206 2012 376 386
42. E. Schleußner Drohende Frühgeburt: Prävention, Diagnostik und Therapie Dtsch Arztebl Int 110 2013 227 236
43. K-J. Chang, T.T.Y. Lee, and G. Linares-Cruz Influences of percutaneous administration of estradiol and progesterone on human breast epithelial cell cycle in vivo Fertil Steril 63 1995 785 791
44. J.M. Foidart, C. Colin, and X. Denoo Estradiol and progesterone regulate the proliferation of human breast epithelial cells Fertil Steril 69 1998 963 969
45. R. Sitruk-Ware, B. Seradour, and C. Lafaye Treatment of benign breast diseases by progesterone applied topically P. Mauvais-Jarvis, C.H.F. Vickers, Percutaneous absorption of steroids 1980 Academic Press London New York, NY 218 229
46. F.Z. Stanczyk, R.J. Paulson, and S. Roy Percutaneous administration of progesterone: blood levels and endometrial protection Menopause 12 2005 232 237
47. B.G. Wren Transdermal progesterone creams for postmenopausal women: more hype than hope? Med J Aust 182 2005 237 239
48. K.A. Burry, P.E. Patton, and K. Hermsmeyer Percutaneous absorption of progesterone in postmenopausal women treated with transdermal estrogen Am J Obstet Gynecol 180 1999 1504 1511
49. S. Zargar-Shoshtari, H. Wahhabaghei, and A. Mehrsai Transdermal delivery of bioidentical progesterone using dutasteride (A 5α-reductase inhibitor): a pilot study J Pharm Pharm Sci 13 2010 626 636
50. B.G. Wren, K. McFarland, and L. Edwards Effect of sequential transdermal progesterone cream on endometrium bleeding pattern, and plasma progesterone and salivary progesterone levels in postmenopausal women Climacteric 3 2000 155 160
51. C. Cooper Spencer, and M.I. Whitehead Systemic absorption of progesterone from progest cream in postmenopausal women Lancet 351 1998 1255 1256
52. B.J. Carey, A.H. Carey, and S. Patel A study to evaluate serum and urinary hormone levels following short and long term administration of two regimens of progesterone cream in postmenopausal women Br J Obstet Gynecol 107 2000 722 726
53. J.G. Lewis, H. McGill, V.M. Patton, and P.A. Elder Caution on the use of saliva measurements to monitor absorption of progesterone from transdermal creams in postmenopausal women Maturitas 41 2002 1 6
54. A. Vashisht, F. Wadsworth, and A. Carey A study to look at hormonal absorption of progesterone cream used in conjunction with transdermal estrogen Gynecol Endocrinol 21 2005 101 105
55. S.A. Missmer, A.H. Eliassen, R.L. Barbieri, and S.E. Hankinson Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women J Natl Cancer Inst 96 2004 1856 1865
56. B. Benster, A. Carey, and F. Wadsworth A double-blind plazebo-controlled study to evaluate the effect of progestelle progesterone cream on postmenopausal women Menopause Int 15 2009 63 69
57. A.C. Hermann, A.N. Nafziger, and J. Victory Over-the-counter progesterone cream produces significant drug exposure compared to a Food and Drug Administration-approved oral progesterone product J Clin Pharmacol 45 2005 614 619
58. M.A. Elshafie, and A.A. Ewies Transdermal natural progesterone cream for postmenopausal women: inconsistent data and complex pharmacokinetics J Obstet Gynaecol 27 2007 655 659
59. P. OÍLeary, P. Feddema, and K. Chan Salivary, but not serum or urinary levels of progesterone are elevated after topical application of progesterone cream to pre- and postmenopausal women Clin Endocrinol 53 2000 615 620
60. J.Y. Du, P. Sanchez, L. Kim, and C.G. Azen Percutaneous progesterone delivery through cream or gel application in postmenopausal women: a randomized cross-over study of progesterone levels in serum, whole blood, saliva, and capillary blood Menopause 20 2013 1169 1175
61. D.T. Zava, M.N. Groves, and F.Z. Stanczyk Percutaneous absorption of progesterone Maturitas 77 2014 91 92
62. Committee for Medicinal Products for Human use (CHMP) Guideline on clinical investigation of medicinal products for hormone replacement therapy of oestrogen deficiency symptoms in postmenopausal women EMEA/CHMP/021/97 Rev. 1 2005 Committee for Medicinal Products for Human use (CHMP) London
63. A. Vashisht, F. Wadsworth, and A. Carey Bleeding profiles and effects on the endometrium for women using a novel combination of transdermal oestradiol and natural progesterone cream as part of a continuous combined hormone replacement regime BJOG 112 2005 1402 1406
64. G. Samsioe, V. Dvorak, and A.R. Genazzani One-year endometrial safety evaluation of a continuous combined transdermal matrix patch delivering low-dose estradiol-norethisterone acetate in postmenopausal women Maturitas 57 2007 171 181
65. D.F. Archer, I.H. Thorneycroft, and M. Foegh Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial Menopause 12 2005 716 727
66. H.B. Leonetti, J. Landes, D. Steinberg, and J.N. Anasti Transdermal progesterone cream as an alternative progestin in hormone therapy Altern Ther Health Med 11 2005 36 38
67. H.B. Leonetti, K.J. Wilson, and J.N. Anasti Topical progesterone cream has an antiproliferative effect on estrogen-stimulated endometrium Fertil Steril 79 2003 221 222
68. B.G. Wren, K. McFarland, and L. Edwards Effect of sequential transdermal progesterone cream on endometrium, bleeding pattern, and plasma progesterone and salivary progesterone levels in postmenopausal women Climacteric 3 2000 155 160
69. North American Menopause Society The 2012 hormone therapy position statement of: The North American Menopause Society Menopause 19 2012 257 271
70. I. Schiff, D. Tulchinsky, D. Cramer, and K.J. Ryan Oral medroxyprogesterone in the treatment of postmenopausal symptoms JAMA 244 1980 1443 1445
71. B.H. Albrecht, I. Schiff, D. Tulchinsky, and K.J. Ryan Objective evidence that plazebo and oral medroxyprogesterone acetate therapy diminish menopausal vasomotor flushes Am J Obstet Gynecol 139 1981 631 635
72. Y. Erlik, D.R. Meldrum, L.D. Lagasse, and H.L. Judd Effect of megestrol acetate on flushing and bone metabolism in post-menopausal women Maturitas 3 1981 167 172
73. C.L. Loprinzi, J.C. Michalak, and S.K. Quella Megestrol acetate for the prevention of hot flashes N Engl J Med 331 1994 347 352
74. I. Schiff The effects of progestins on vasomotor flushes J Reprod Med 27 1982 498 502
75. C.L. Hitchcock, and J.C. Prior Oral micronized progesterone for vasomotor symptoms - a plazebo-controlled randomized trial in healthy postmenopausal women Menopause 19 2012 886 893
76. C.L. Loprinzi, R. Levitt, and D. Barton Phase III comparison of depomedroxyprogesterone acetate to venlafaxine for managing hot flashes: North Central Cancer Treatment Group Trial N99C7 J Clin Oncol 24 2006 1409 1414
77. J.W. Goodwin, S.J. Green, and C.M. Moinpour Phase III randomized plazebo-controlled trial of two doses of megestrol acetate as treatment for menopausal symptoms in women with breast cancer: Southwest Oncology Group Study 9626 J Clin Oncol 26 2008 1650 1656
78. C.L. Loprinzi, D.L. Barton, and R. Qin Nonestrogenic management of hot flashes J Clin Oncol 29 2011 3842 3846
79. A.M. Whelan, T.M. Jurgens, and M. Trinacty Bioidentical progesterone cream for menopause-related vasomotor symptoms: is it effective Ann Pharmacother 47 2013 112 116
80. H.B. Leonetti, S. Longo, and J.N. Anasti Transdermal progesterone cream for vasomotor symptoms and postmenopausal bone loss Obstet Gynecol 94 1999 225 228
81. B.G. Wren, S.M. Champion, and K. Willetts Transdermal progesterone and its effect on vasomotor symptoms, blood lipid levels, bone metabolic markers, moods, and quality of life for postmenopausal women Menopause 10 2003 13 18
82. US Department of Health and Human Services. FDA Guidance for industry: estrogen and estrogen/progestin drug products to treat vasomotor symptoms and vulvar and vaginal atrophy symptoms - recommendations for clinical evaluation 2003 US Department of Health and Human Services, FDA Washington, DC
83. K. Stephenson, P.F. Neuenschwander, and A.K. Kurdowska Transdermal progesterone: effects on menopausal symptoms and on thrombotic, anticoagulant, and inflammatory factors in postmenopausal women Int J Pharm Compd 12 2008 295 304
84. B. Benster, A. Carey, and F. Wadsworth Double-blind placebo-controlled study to evaluate the effect of pro-juven progesterone cream on atherosclerosis and bone density Menopause Int 15 2009 100 106
85. T.J. de Villiers, A. Pines, and N. Panay International Menopause Society Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health Climacteric 16 2013 316 337
86. S. Zargar-Shoshtari, H. Wahhabaghei, A. Mehrsai, J. Wen, and R. Alany Transdermal delivery of bioidentical progesterone using dutasteride (a 5α-reductase inhibitor): a pilot study J Pharm Pharm Sci 13 2010 626 636
87. B. Formby, and F. Schmidt Efficacy of biorhythmic transdermal combined hormone treatment in relieving climacteric symptoms: a pilot study Int J Gen Med 4 2011 159 163
88. C. Mircioiu, A. Perju, E. Griu, G. Calin, A. Neagu, D. Enachescu, and D.S. Miron Pharmacokinetics of progesterone in postmenopausal women: 2 pharmacokinetics following percutaneous administration Eur J Drug Metab Pharmacokinet 23 1998 397 402